Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in
G protein-coupled receptor kinase 2 (GRK2) has emerged as a key regulator of cardiac function and myocardial structure. Cardiac GRK2 is increased in heart failure and ischemia in humans, whereas genet
COL I : collagen type I, COL III: collagen type III, α-MHC: alpha-myosin heavy chain, β-MHC: beta-myosin heavy chain, SERCA2A: sarco/endoplasmatic reticulum calcium ATPase, GLUT1: glucose transporter
